

Drug Eligible for Billing C9399

July 2023



Generic Name	Brand Name	FDA Approval Date	Route*	Company	Package Insert
Abaloparatide	Tymlos	4/28/2017	Subcutaneous	Radius Health	Tymlos PI
Adalimumab-adaz	Hyrimoz	10/30/2018	Subcutaneous	Sandoz	Hyrimoz PI
Adalimumab-adbm	Cyltezo	8/25/2017	Subcutaneous	Boehringer Ingelheim	Cyltezo PI
Adalimumab-afzb	Abrilada	11/15/2019	Subcutaneous	Pfizer	Abrilada PI
Adalimumab-aqvh	Yusimry	12/17/2021	Subcutaneous	Coherus Biosciences	Yusimry PI
Adalimumab-atto	Amjevita	9/23/2016	Subcutaneous	Amgen	Amjevita PI
Adalimumab-bwwd	Hadlima	7/23/2019	Subcutaneous	Merck, Sharp & Dohme	Hadlima PI
Amisulpride	Barhemsys	2/26/2020	IV infusion	Acacia Pharma	Barhemsys PI
Angiotensin-II	Giapreza	12/21/2017	IV infusion	La Jolla Pharmaceutical	Giapreza PI
Ansumimab-zykl	Ebanga	12/21/2020	IV infusion	Ridgeback	Ebanga PI
Betibeglogene autotemcel	Zynteglo	8/17/2022	IV infusion	Bluebird Bio Inc	Zynteglo PI
Brivaracetam injection	Briviact	2/18/2016	IV push	UCB	Briviact PI
Bupivacaine solution for infiltration use	Posimir	2/1/2021	Infiltration	Durect Corp	Posimir PI
Buprenorphine	Brixadi	5/23/2023	Subcutaneous	Braeburn Pharma Inc	Brixadi PI
Chlorprocaine	Clorotekal	9/26/2017	Intrathecal	B. Braun	Clorotekal PI
Cyclophosphamide	Cyclophosphamide	6/7/2023	IV infusion	Dr Reddys Labs Ltd	Cyclophosphamide PI
Dantrolene (special formulation)	Ryanodex	7/22/2014	IV push	Eagle Pharmaceuticals	Ryanodex PI
DaxibotulinumtoxinA-inj	Daxxify	9/7/2022	IM injection	Revance Therapeutics Inc	Daxxify PI
Defibrotide	Defitelio	3/30/2016	IV infusion	Jazz Pharmaceuticals	Defitelio PI
Desiglucon	Zegalogue	3/22/2021	Subcutaneous	Zealan Pharma A/S	Zegalogue PI
Dinutuximab	Unituxin	3/10/2015	IV infusion	United Therapeutics	Unituxin PI
Donislecel-juj	Lantrida	6/28/2023	Hepatic portal vein infusion	CellTrans Inc	Lantidra PI
Elapegedemase-inj	Revcovi	10/5/2018	Intramuscular	Leadiant Biosciences	Revcovi PI
Elivaldogene autotemcel	Skysona	9/16/2022	IV infusion	Bluebird Bio Inc	Skysona PI
Epinephrine	Epinephrine**	4/21/2023	IV infusion	Par Sterile Products	Epinephrine PI
Erenumab-aooe	Aimovig	5/17/2018	Subcutaneous	Amgen	Aimovig PI
Etanercept-szsz	Erelzi	8/30/2016	Subcutaneous	Sandoz	Erelzi PI
Etanercept-ykro	Eticovo***	4/25/2019	Subcutaneous	Samsung Bioepis	Eticovo PI
Evolocumab	Repatha	8/27/2015	Subcutaneous	Amgen	Repatha PI

Drug Eligible for Billing C9399

July 2023



Generic Name	Brand Name	FDA Approval Date	Route*	Company	Package Insert
Fentanyl Citrate	Fentanyl Citrate	2/8/2023	IV infusion	Exela Pharma	Fentanyl PI
Flotufolastat F-18	Posluma	5/25/2023	IV infusion	Blue Earth Diagnostics Ltd.	Posluma PI
Fosdenopterin	Nulibry	2/26/2021	IV infusion	Origin Biosciences	Nulibry PI
Galcanezumab-gnlm	Emgality	9/27/2018	Subcutaneous	Lilly	Emgality PI
Human fibrinogen, human thrombin	Vistaseal	11/1/2019	Topical	Grifols USA	Vistaseal PI
Idarucizumab	Praxbind	10/16/2015	IV bolus; IV infusion	Portola Pharmaceuticals	Praxbind PI
Inotersen	Tegsedi	10/5/2018	Subcutaneous	Akcea Therapeutics	Tegsedi PI
Insulin glargine-aglr	Tezvoglar	12/17/2021	Subcutaneous; IV infusion	Lilly	Rezvoglar PI
Insulin Glargine-Aglr	Rezvoglar	11/16/2022	Subcutaneous	Eli Lilly and Company	Rezvoglar PI
Insulin lispro-aabc	Lyumjev	6/15/2020	Subcutaneous; IV infusion	Lilly	Lyumjev PI
Lecanemab-lrmb	Legembi	1/6/2023	IV infusion	Eisai Inc	Legembi PI
Letermovir	Prevymis	11/8/2017	IV infusion	Merck, Sharp & Dohme	Prevymis PI
Lonapegsomatropin-tcgd	Skytrofa	8/25/2021	Subcutaneous	Ascendis Pharma	Skytrofa PI
Hydroxyethylamine Blue (for methemoglobinemia)	Provayblue	4/8/2016	IV push; IV infusion	American Regent	Provayblue PI
Neostigmine Methylsulfate and Glycopyrrolate	Prevduo	2/23/2023	IV infusion	Slayback Pharma LLC	Prevduo PI
Obiltoximab	Anthim	3/18/2016	IV infusion	Elusys Therapeutics	Anthim PI
Pafolacianine sodium	Cytalux	11/29/2021	IV infusion	On Target Labs	Cytalux PI
Pegcetacoplan	Empaveli	5/14/2021	Subcutaneous infusion	Apellis Pharmaceuticals	Empaveli PI
Pegvaliase-pqpz	Palynziq	5/24/2018	Subcutaneous	BioMarin Pharmaceutical	Palynziq PI
Posaconazole injection	Noxafil	3/13/2014	IV infusion	Merck, Sharp & Dohme	Noxafil PI
Prabotulinum Toxin A-xvfs	Jeuveau	2/1/2019	Intramuscular	Evolus	Jeuveau PI
Retifanlimab-Dlwr	Zynzy	3/22/2023	IV infusion	Incyte Corp	Zynzy PI
Risperidone	Uzedy**	4/28/2023	IM injection	Teva Neuroscience Inc	Uzedy PI
Ropeginteron alfa-2b-njft	Besremi	11/12/2021	Subcutaneous	Pharmaesentia	Besremi PI
Sarilumab	Kevzara	5/22/2017	Subcutaneous	Sanofi-Aventis	Kevzara PI
Satralizumab	Enspryng	8/14/2020	Subcutaneous	Genentech	Enspryng PI
Selexipag injection	Uptravi	7/29/2021	IV infusion	Actelion	Uptravi PI
Semaglutide	Ozempic	12/5/2017	Subcutaneous	Novo Nordisk	Ozempic PI
Semaglutide	Wegovy**	6/4/2021	Subcutaneous	Novo Nordisk	Wegovy PI

Drug Eligible for Billing C9399

July 2023



Generic Name	Brand Name	FDA Approval Date	Route*	Company	Package Insert
Setmelanotide	Imcivree**	11/25/2020	Subcutaneous	Rhythm Pharm	Imcivree PI
Somapacitan-beco	Sogroya	8/28/2020	Subcutaneous	Novo Nordisk	Sogroya PI
Sugammadex	Bridion**	12/15/2015	IV push	Merck, Sharp & Dohme	Bridion PI
Sulbactam;Durlobactam	Xacduro	5/23/2023	IV infusion	Entasis Therapeutics Inc	Xacduro PI
Technetium Tc-99m Mertiatide Kit	m Tc-99m Mer	1/30/2023	IV infusion	Jubilant Draximage	Tc-99 Mertiatide
Tecovirimat	Tpoxx	5/18/2022	IV infusion	Siga Tech	Tpoxx PI
Teduglutide [rDNA origin]	Gattex	12/21/2012	Subcutaneous	Shire-NPS Pharma	Gattex PI
Terlipressin	Terlivaz	9/14/2022	IV bolus injection	Mallinckrodt	Terlivaz PI
Tirzepatide	Mounjaro	5/13/2022	Subcutaneous	Lilly	Mounjaro PI
Tralokinumab-ldrm	Adbry	12/27/2021	Subcutaneous	Leo Pharma AS	Adbry PI
Valoctocogene roxaparvovec-rvox	Roctavian	6/30/2023	IV infusion	BioMarin Pharmaceutical Inc.	Roctavian PI
Vosorotide	Voxzogo	11/19/2021	Subcutaneous	BioMarin Pharmaceutical	Voxzogo PI

*Note some payers may cover subcutaneous injections under a Pharmacy benefit rather than the Medical benefit

** Must be administered by a healthcare professional

Updated: 07/04/2023

The Pharmacy Revenue Cycle internet web site provides "hyperlinks" to other internet web sites that contain information created, published, maintained or otherwise posted by institutions or organizations independent of the developers of the Pharmacy Revenue Cycle website. We do not endorse, approve, certify or control those external web sites, and we do not guarantee the accuracy, completeness, efficacy or timeliness of information located at those sites. Use of any information obtained from those web sites is voluntary, and reliance on that information should only be undertaken after an independent review of its accuracy. "Tools" are posted as pdf files with a date stamp to preserve the time-sensitivity of the external information that was used to develop the tool. Use of our "Tools" is voluntary and the information should be independently reviewed for accuracy and applicability to your situation.